BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myelodysplastic Syndromes readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Myelodysplastic Syndr
 omes\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06304103-899@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AND017: Phase 2 readout est. (NCT06304103)
DESCRIPTION:AND017\, phase 2\, Myelodysplastic Syndromes.\nStudy: A Study o
 f Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/and017#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06304103
URL:https://assetmemo.bio/drug/and017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788679-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05788679)
DESCRIPTION:Azacitidine\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects Wit
 h MDS\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05788679
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00392353-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT00392353)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Vorin
 ostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes 
 or Acute Myeloid Leukemia\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT00392353
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584761-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05584761)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Unrel
 ated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatm
 ent for Advanced MDS\,CMML-2 and sAML\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitid
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05584761
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428969-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT05428969)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy to Assess Safety\, Tolerability and Preliminary Efficacy of Bexmarilima
 b in Combination With Standard of Care in Patients With Hematological Mali
 gnancies\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05428969
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988555-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Pha
 se 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Hori
 zen-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847867-3097@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Momelotinib: Phase 2 readout est. (NCT06847867)
DESCRIPTION:Momelotinib\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome\
 nEstimated primary completion: 14 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06847867
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672769-2934@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Bexmarilimab: Phase 2 readout est. (NCT07672769)
DESCRIPTION:Bexmarilimab\, phase 2\, Higher-Risk Myelodysplastic Syndromes.
 \nStudy: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Partic
 ipants With Treatment-naïve Higher-risk Myelodysplastic Syndromes\nEstima
 ted primary completion: November 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bexmarilimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07672769
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04256317-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT04256317)
DESCRIPTION:Azacitidine\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Mul
 ti-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neopla
 sm Alone or in Combination With Venetoclax in AML (AZTOUND Study)\nEstimat
 ed primary completion: 1 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04256317
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465953-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Azacitidine: Phase 3 readout est. (NCT06465953)
DESCRIPTION:Azacitidine\, phase 3\, Myelodysplastic Syndromes.\nStudy: Ivos
 idenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients Wit
 h Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With a
 n IDH1 Mutation\nEstimated primary completion: 1 November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06465953
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05308264-10823@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:R289: Phase 1/2 readout est. (NCT05308264)
DESCRIPTION:R289\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: Study of 
 R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)\nEstim
 ated primary completion: December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/r289#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05308264
URL:https://assetmemo.bio/drug/r289#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885397-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT07885397)
DESCRIPTION:Azacitidine\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: So
 nrotoclax Plus Azacitidine in Patients With MDS-IB2\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07885397
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04093570-2362@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT04093570
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Acute Myeloid Leuk
 emia.\nStudy: A Study for Participants Who Participated in Prior Clinical 
 Studies of ASTX727 (Standard Dose)\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/decitabine-
 cedazuridine-inqovi#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04093570
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05365035-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05365035)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: A Ph
 ase II Study of Cladribine and Low Dose Cytarabine in Combination With Ven
 etoclax\, Alternating With Azacitidine and Venetoclax\, in Patients With H
 igher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-ri
 sk Myelodysplastic Syndromes With Excess Blasts\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/azacitidine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05365035
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201066-2362@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 2 readout est. (NCT05201066
 )
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 2\, Myelodysplastic Sy
 ndromes.\nStudy: Roll-over Study for Patients Who Have Completed a Prior N
 ovartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investi
 gator to Benefit From Continued Treatment With Sabatolimab.\nEstimated pri
 mary completion: 14 February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05201066
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201066-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Azacitidine: Phase 2 readout est. (NCT05201066)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: Roll
 -over Study for Patients Who Have Completed a Prior Novartis-sponsored Sab
 atolimab (MBG453) Study and Are Judged by the Investigator to Benefit From
  Continued Treatment With Sabatolimab.\nEstimated primary completion: 14 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azaciti
 dine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05201066
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319845-11364@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Elritercept: Phase 2 readout est. (NCT07319845)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodyspla
 stic Syndromes\nEstimated primary completion: 26 June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07319845
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04771130-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT04771130)
DESCRIPTION:Azacitidine\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Stu
 dy of BGB-11417 in Participants With Myeloid Malignancies\nEstimated prima
 ry completion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04771130
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932873-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Azacitidine: Phase 2/3 readout est. (NCT07932873)
DESCRIPTION:Azacitidine\, phase 2/3\, Myelodysplastic Syndromes.\nStudy: So
 nrotoclax in Combination With Azacitidine for Previously Untreated Higher-
 risk Myelodysplastic Syndromes\nEstimated primary completion: 1 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793287
 3
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06499285-11364@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Elritercept: Phase 3 readout est. (NCT06499285)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Trans
 fusions\nEstimated primary completion: 15 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06499285
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422480-11364@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Elritercept: Phase 3 readout est. (NCT07422480)
DESCRIPTION:Elritercept\, phase 3\, Myelodysplastic Syndromes.\nStudy: A St
 udy to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults Wit
 h Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Tra
 nsfusions\nEstimated primary completion: 30 April 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elritercept#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07422480
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047183-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Azacitidine: Phase 2 readout est. (NCT07047183)
DESCRIPTION:Azacitidine\, phase 2\, Myelodysplastic Syndromes.\nStudy: Clin
 ical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Pri
 or to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk
  Myelodysplastic Syndromes\nEstimated primary completion: 30 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/azacitidine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07047183
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471946-2832@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Azacitidine: Phase 1/2 readout est. (NCT06471946)
DESCRIPTION:Azacitidine\, phase 1/2\, Myelodysplastic Syndromes.\nStudy: VA
  Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS\nEstimated pri
 mary completion: 1 September 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/azacitidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06471946
URL:https://assetmemo.bio/drug/azacitidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04419649-11364@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Elritercept: Phase 2 readout est. (NCT04419649)
DESCRIPTION:Elritercept\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Elritercept to Treat Anemia in Adults With Very Low\, Low\, or Inte
 rmediate Risk Myelodysplastic Syndromes (MDS)\nEstimated primary completio
 n: 30 October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 lritercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04419649
URL:https://assetmemo.bio/drug/elritercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722988-873@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Evrenzo (Roxadustat): Phase 3 readout est. (NCT07722988)
DESCRIPTION:Evrenzo (Roxadustat)\, phase 3\, Myelodysplastic Syndromes.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592
 ) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
 \nEstimated primary completion: September 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/roxadustat#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07722988
URL:https://assetmemo.bio/drug/roxadustat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04742634-2362@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Decitabine/cedazuridine (Inqovi): Phase 1/2 readout est. (NCT047426
 34)
DESCRIPTION:Decitabine/cedazuridine (Inqovi)\, phase 1/2\, Myelodysplastic 
 Syndromes.\nStudy: Pre-emptive Therapy With DEC-C to Improve Outcomes in M
 DS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic
  Cell Transplant\nEstimated primary completion: 30 November 2033. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/decitabine-cedazuridine-inqov
 i#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 742634
URL:https://assetmemo.bio/drug/decitabine-cedazuridine-inqovi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
